
Loading, please wait...

Loading, please wait...

Recent research has shed light on the complex nature of nsLTP allergen cross-reactivity through the discovery of a unique human monoclonal antibody, IGX-3103. Nonspecific lipid transfer proteins (nsLTPs) often cause systemic allergic reactions to various plant foods. For clinicians, distinguishing between true cosensitization and broad cross-reactivity in allergic patients is a major diagnostic hurdle. However, this study suggests that a single, promiscuous antibody may drive the multi-source sensitivity seen in many patients. Specifically, researchers cloned IGX-3103 from memory B cells using single-cell sequencing.
Moreover, researchers discovered that this antibody binds to 19 different type 1 nsLTP allergens. In addition, crystallographic analysis showed that the antibody induces a conformational change in the allergen. This allows a specific residue, Phe104, to penetrate the lipid-binding cavity. Because key residues like Leu1 and Ser2 are conserved across plant species, the antibody reacts with allergens from fruits, seeds, and pollens. Thus, this mechanism explains why some patients react to so many different sources.
As a result, the discovery of IGX-3103 confirms that a few promiscuous antibodies can cause widespread food sensitivity. This supports the idea that cross-reactivity often stems from shared epitopes. Consequently, doctors can better understand why patients test positive for multiple unrelated plant extracts. These findings help in developing more precise diagnostic tools. Furthermore, they allow for more personalized management of patients with complex allergy profiles. Therefore, understanding this antibody could improve clinical outcomes significantly.
Non-specific lipid transfer proteins (nsLTPs) are stable plant proteins found in many fruits, vegetables, and nuts. They are highly resistant to heat and digestion, often leading to severe systemic allergic reactions.
IGX-3103 is a promiscuous monoclonal antibody that can bind to many different nsLTPs. Its existence suggests that broad food allergies may be caused by a small number of cross-reactive antibodies rather than many specific ones.
Diagnosis is challenging because the structural similarity between nsLTPs in different foods leads to widespread cross-reactivity. This makes it hard to identify the primary sensitizing food using standard polyclonal serum tests.
Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A study identifies IGX-3103, a human monoclonal antibody that binds 19 different nsLTP allergens, explaining the mechanism behind broad food cross-reactivit...
8 months ago

Discover the crucial role of glymphatic dysfunction in stroke, where perivascular clearance failure and neuroinflammation exacerbate cerebral edema and post-stroke brain injury.
Today

A prenatal case highlights severe glutaric acidemia type II presenting as bilateral hyperechoic cystic kidneys at 18 weeks. Whole-exome sequencing revealed a novel homozygous ETFDH frameshift variant, demonstrating the power of rapid genetic testing in fetal renal anomalies.
Today

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Yesterday